|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
5 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating expenses: | |||||
| Selling, general and administrative | |||||
| Research and development | |||||
| Acquired in-process research and development | |||||
| Change in fair value of contingent consideration | |||||
| Total operating costs and expenses | |||||
| (Loss) income from operations | |||||
| Other (loss) income: | |||||
| Change in fair value of convertible notes | |||||
| Change in fair value of warrants | |||||
| Loss on embedded forward purchase agreements and derivative liabilities, net | |||||
| Loss on embedded forward purchase agreements | |||||
| Loss on derivative liability | |||||
| Other income, net | |||||
| Total other loss, net | |||||
| (Loss) income before taxes | |||||
| Income taxes | |||||
| (Loss) income and comprehensive (loss) income | |||||
| Net (loss) income | |||||
| Basic net (loss) income per share (in dollars per share) | |||||
| Total basic net (loss) income per share (in dollars per share) | |||||
| Diluted net (loss) income per share (in dollars per share) | |||||
| Total diluted net (loss) income per share (in dollars per share) | |||||
| Weighted average shares of common stock outstanding used to compute basic net (loss) income per share | |||||
| Total weighted average shares of common stock outstanding used to compute basic net (loss) income per share | |||||
| Weighted average shares of common stock outstanding used to compute diluted net (loss) income per share | |||||
| Total weighted average shares of common stock outstanding used to compute diluted net (loss) income per share | |||||
Loading...